Lamotrigine monotherapy for newly diagnosed typical absence seizures in children: A multi-center, uncontrolled, open-label study

Brain and Development

Volumn 38, Issue 4, 2016, Pages 407-413

  Yasumoto, Sawa ^a   Shimizu, Masahiro ^b   Sato, Katsuaki ^b   Kurata, Atsuyo ^b   Numachi, Yotaro ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b Development and Medical Affairs Division   (Japan)

Author keywords

Children; Lamotrigine; Monotherapy; Typical absence seizures

Indexed keywords

LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ABSENCE; ANTICONVULSANT THERAPY; ARTICLE; BRONCHITIS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; HEADACHE; HUMAN; JAPANESE (PEOPLE); MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PEDIATRICS; RASH; RHINOPHARYNGITIS; SCARLET FEVER; SOUTH KOREAN; STOMATITIS; SUICIDE; TREATMENT DURATION; TYPICAL ABSENCE SEIZURE; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; CLINICAL TRIAL; EPILEPSY, ABSENCE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; FEMALE; HUMANS; MALE; TREATMENT OUTCOME; TRIAZINES;

EID: 84959203619     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2015.10.007     Document Type: Article

References (9)

1. Frank L.M., Enlow T., Holmes G.L., Manasco P., Concannon S., Chen C., et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999, 40:973-979.
2. Holmes G.L., Frank L.M., Sheth R.D., Philbrook B., Wooten J.D., Vuong A., et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008, 82:124-132.
3. National Institute for Health and Care Excellence (NICE) The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE clinical guideline 137 2012, Available from: [issued January 2012; last modified December 2013].
4. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Guerreiro C., Kälviäinen R., et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013, 54:551-563.
5. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007, 9:353-412.
6. Commission on Classification and Terminology of the International League against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22:489-501.
7. Glauser T.A., Cnaan A., Shinnar S., Hirtz D.G., Dlugos D., Masur D., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013, 54:141-155.
8. Coppola G., Auricchio G., Federico R., Carotenuto M., Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004, 45:1049-1053.
9. Hirsch E., Panayiotopoulos C.P. Childhood absence epilepsy and related syndromes. Epileptic syndromes in infancy, childhood and adolescence 2005, 315-335. John Libbey Eurotext Ltd, Montrouge. fourth ed.